Function of cannabinoids in heart failure;Znaczenie kannabinoidów w niewydolnos̈ci serca

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 174-184

  Rudź, Radosław ^a   Baranowska, Urszula ^a   Malinowska, Barbara ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cannabinoids; Cardiogenic shock; CB1 receptor; CB2 receptor; Heart failure

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

DRUG EFFECT; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; REVIEW; VASCULAR ENDOTHELIUM;

CANNABINOIDS; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; VENTRICULAR REMODELING;

EID: 45349100935     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Aronow W.S., Cassidy J.: Effects of marijuana and placebo-marijuana smoking on angina pectoris. N. Engl. J. Med., 1974; 291: 65-67
2. Bachs L., Morland H.: Acute cardiovascular fatalities following cannabis use. Forensic Sci. Int., 2001; 124: 200-203
3. Batkai S., Pacher P., Jarai Z., Wagner J.A., Kunos G.: Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by cardaic mechanism not involving CB1 or CB2 receptors. Am. J. Physiol. Heart Circ. Physiol., 2004; 287: H595.H600
4. Batkai S., Pacher P., Osei-Hyiaman D., Radaeva S., Liu J., Harvey-White J., Offertaler L., Mackie K., Rudd M.A., Bukoski R.D., Kunos G.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation, 2004; 110: 1996-2002
5. Begg M., Mo F.M., Offertaler L., Batkai S., Pacher P., Razdan R.K., Lovinger D.M., Kunos G.: G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. J. Biol. Chem., 2003; 278: 46188-46194
6. Benowitz N.L., Jones R.T.: Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin. Pharmacol. Ther., 1975; 18: 287-297
7. Bilfinger T.V., Salzet M., Fimiani C., Deutsch D.G., Stefano G.B.: Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int. J. Cardiol., 1998; 64(Suppl.1): S15.S22
8. Bisogno T., Katayama K., Melck D., Ueda N., De Petrocellis L., Yamamoto S., Di Marzo V.: Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cell. Implications for cell proliferation and differentiation. Eur. J. Biochem., 1998; 254: 634-642
9. Bonz A., Laser M., Kullmer S., Kniesch S., Babin-Ebell J., Popp V., Ertl G., Wagner J.A.: Cnabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol., 2003; 41: 657-664
10. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P.: Cannabinoid-receptor expression In human leukocytes. Eur. J. Biochem., 1993; 214: 173-180
11. Bouchard J.F., Lepicier P., Lamontagne D.: Contribution of endocannabioids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci., 2003; 72: 1859-1870
12. Califf R.M., Bengtson J.R.: Cardiogenic shock. N. Engl. J. Med. 1994; 330: 1724-1730
13. Chataigneau T., Feletou M., Thollon C., Villeneuve N., Vilaine J.P., Duhault J., Vanhoutte P.M.: Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br. J. Pharmacol., 1998; 123: 968-974
14. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mendelbaum A., Etinger A., Mechoulam R.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992; 258: 1946-1949
15. Di Filippo C., Rossi F., Rossi S., D'Amico M.: Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol., 2004; 75: 453-459
16. Di Marzo V.: Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci., 1999; 65: 645-655
17. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W.: Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in the brain and peripheral tissues of human and rat. FEBS Lett., 1996; 393: 231-235
18. Ford W.R., Honan S.A., White R., Hiley C.R.: Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol., 2002; 135: 1191-1198
19. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P.: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995; 232: 54-61
20. Gaoni Y., Mechoulam R.: Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc., 1964; 86: 1646-1647
21. Gerard C.M, Mollereau C, Vassart G, Parmentier M.: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J., 1991; 279: 129-134
22. Gerard C.M, Mollereau C, Vassart G, Parmentier M.: Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res., 1990; 18: 7142
23. Godlewski G., Malinowska B., Schlicker E.: Presynaptic cannabinoid CB1 receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br. J. Pharmacol., 2004; 142: 701-708
24. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., Shohami E., Spatz M.: Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors, Brain Res. Mol. Brain Res., 2004; 132: 87-92
25. Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA.: The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am. Heart J., 2006; 151: 754.e1-754.e5
26. Grainger J., Boachie-Ansah G.: Anandamide-induced relaxation of sheep coronary arteries: The role of the vascular endothelium, arachidonic acid metabolites and potassium chanels. Br. J. Pharmacol., 2001; 134: 1003-1012
27. Hajos N., Ledent C., Freund T.F.: Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 2001; 106: 1-4
28. Harris D., McCulloch A.I., Kendall D.A., Randall M.D.: Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J. Physiol., 2002; 539: 893-902
29. Hiley C.R., Ford W.R.: Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol. Rev. Camb. Philos. Soc., 2004; 79: 187-205
30. Hollenberg S.M.: Recognition and treatment of cardiogenic shock. Semin. Respir. Crit. Care. Med., 2004; 25: 661-671
31. Hollenberg S.M., Kavinsky C.J., Parrillo J.E.: Cardiogenic shock. Ann. Intern. Med., 1999; 131: 47-59
32. Ishac E.J.N., Jiang L., Lake K.D., Varga K., Abood M.E., Kunos G.: Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol., 1996; 118: 2023-2028
33. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G.: Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA, 1999; 96: 14136-14141
34. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., Ribuot C.: Endocannabinoids are implicated in the infarct sizereducing effect conferred by a heat stress preconditioning in isolated rat hearts. Cardiovasc. Res., 2002; 55: 619-625
35. Kenny L.C., Baker P.N., Kendall D.A., Randall M.D., Dunn W.R.: The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br. J. Pharmacol., 2002; 136: 1085-1088
36. Komorowski J., Stêpieñ H.: Rola ukadu endokannabinoidowego w regulacji czynnoci dokrewnej i kontroli równowagi energetycznej czowieka. Post. Hig. Med. Dow., 2007; 61: 99-105
37. Kozowska H., Baranowska M., Schlicker E., Kozowski M., Malinowska B.: Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery; J. Hypertens., 2007; 25: 2240-2248
38. Krylatov A.V., Ugdyzhekova D.S., Bernatskaya N.A., Maslov L.N., Mechoulam R., Pertwee R., Stephano G.B.: Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull. Exp. Biol. Med., 2001; 131: 523-525
39. Krylatov A.V., Uzhachenko R.V., Maslow L.N., Bernatskaya N.A., Makriyannis A., Mechoulam R., Pertwee R.G., Salnikova O.M., Stefano J.B., Lishmanov Y.: Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull. Exp. Biol., 2002; 133: 122-124
40. Krylatov A.V., Uzhachenko R.V., Maslov L.N., Ugdyzhekova D.S., Bernatskaia N.A., Pertwee R., Stefano G.B., Makriyannis A.: Anandamide and R-(+)-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2 receptors. Eksp. Klin. Farmakol., 2002; 65: 6-9
41. Kumar R.N., Chambers W.A., Pertwee R.G.: Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 2001; 56: 1059-1068
42. Kunos G., Batkai S.: Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem. Res., 2001; 26: 1015-1021
43. Kunos G., Batkai S., Offertaler L., Mo F., Liu J., Karcher J., Harvey-White J.: The quest for a vascular endothelial cannabinoid receptor. Chem. Phys. Lipids., 2002; 121: 45-56
44. Lagneux C., Adam A., Lamontagne D.: A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int. Immunopharmacol., 2003; 3: 1511-1518
45. Lagneux C., Lamontagne D.: Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol., 2001; 132: 793-796
46. Lake K.D., Martin B.R., Kunos G., Varga K.: Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension, 1997; 29: 1204-1210
47. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bõhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M.: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 1999; 283: 401-404
48. Lepicier P., Bibeau-Poirier A., Lagneux C., Servant M.J., Lamontagne D.: Signaling pathways involved in the cardioprotective effects of cannabinoids. J. Pharmacol. Sci., 2006; 102: 155-166
49. Lepicier P., Bibeau-Poirier A., Lagneux C., Sirois M.G., Servant M., Lamontagne D.: Endothelial CB1 receptors confer cardiac protection through nitric oxide production. J. Mol. Cell. Cardiol., 2004; 37: 197-198
50. Lepicier P., Bouchard J.F., Lagneux C., Lamontagne D.: Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol., 2003; 139: 805-815
51. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolkar A.D., Makriyannis A., Kunos G.: Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J., 2000; 346: 835-840
52. Malinowska B., Godlewski G., Bucher B., Schlicker E.: Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedeberg's Arch. Pharmacol., 1997; 356: 197-202
53. Malinowska B., Kwolek G., Gothert M.: Anandamide and methanandamide induce both vanilloid VR1-and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch. Pharmacol., 2001; 364: 562-569
54. Malinowska B., Piszcz J., Koneczny B., Hryniewicz A., Schlicker E.: Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2001; 364: 233-241
55. Mathew R.J., Wilson W.H., Humphreys D.F., Lowe J.V., Wiethe K.E.: Regional cerebral blood flow after marijuana smoking. J. Cereb. Blood Flow Metab., 1992; 12: 750-758
56. Mendizabal V.E., Adler-Graschinsky E.: Cannabinoids as therapeutic agents in cardiovascular disease: A tale of passions and illusions. Br. J. Pharmacol., 2007; 151: 427-440
57. Mittleman M.A., Lewis R.A., Maclure M., Sherwood J.B., Muller J.E.: Triggering myocardial infarction by marijuana. Circulation, 2001; 103: 2805-2809
58. Mohaved P., Evilevitch V., Andersson T.L., Jonsson B.A., Wollmer P., Zygmunt P.M., Hogestatt E.D.: Vascular effects of anandamide and N-acylvanillylamines in the human and skin microcirculation. Br. J. Pharmacol., 2005; 146: 171-179
59. Molderings G.J., Likungu J., Gothert M.: Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch. Pharmacol., 1999; 360: 157-164
60. Mukhopadhyay P., Batkai S., Rajesh M., Czifra N., Harvey-White J., Hasko G., Zsengeller Z., Gerard N., Liaudet L., Kunos G., Pacher P.: Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol., 2007; 50: 528-536
61. Muller J.E., Tofler G.H., Nesto R.W.: Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J. Am. Coll. Cardiol., 1994; 23: 809-813
62. Pacher P., Batkai S., Kunos G.: Cardiovascular pharmacology of cannabinoids. Handb. Exp. Pharmacol., 2005; 168: 599-625
63. Pacher P., Batkai S., Kunos G.: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev., 2006; 58: 389-462
64. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C.: Characterization of a novel cannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002; 301: 1020-1024
65. Ralevic V.: Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur. J. Pharmacol., 2003; 472: 1-21
66. Randall M.D., Kendall D.A., O'Sullivan S.: The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol., 2004; 142: 20-26
67. Sagan S., Venance L., Torrens Y., Cordier J., Glowinski J., Giaume C.: Anandamide and WIN 55,212-2 inhibit cyclic AMP-formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci., 1999; 11: 691-699
68. Schlicker E., Kathmann M.: Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 2001; 22: 565-572
69. Shmist Y.A., Goncharov I., Eichler M., Shneyvays V., Isaac A., Vogel Z., Shainberg A.: Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol. Cell. Biochem., 2006; 283: 75-83
70. Stella N., Schweitzer P., Piomelli D.: A second endogenous cannabinoid that modulates long-term potentiaton. Nature. 1997; 388: 773-778
71. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K.: Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun., 1998; 243: 838-843
72. Ugdyzhekova D.S., Krylatov A.V., Bernatskaya N.A., Maslow L.N., Mechoulam R., Pertwee R.G.: Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull. Exp. Biol. Med., 2002; 133: 125-126
73. Underdown N.J., Hiley C.R., Ford W.R.: Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br. J. Pharmacol., 2005; 146: 809-816
74. Varga K., Wagner J.A., Bridgen D.T., Kunos G.: Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxininduced hypotension. FASEB J. 1998; 12: 1035-1044
75. Wagner J.A., Abesser M., Harvey-White J., Ertl G.: 2-arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J. Cardiovasc. Pharmacol., 2006; 47: 650-655
76. Wagner J.A., Abesser M., Karcher J., Laser M., Kunos G.: Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted upaced rat isolated hearts. J. Cardiovasc. Pharmacol., 2005; 46: 348-355
77. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K., Kunos G., Ertl G.: Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol., 2001; 38: 2048-2054
78. Wagner J.A., Hu K., Karcher J., Bauersachs J., Schafer A., Laser M., Han H., Ertl G.: CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in the rats with myocardial infarction. Br. J. Pharmacol., 2003; 138: 1251-1258
79. Wagner J.A., Jarai Z., Batkai S., Kunos G.: Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur. J. Pharmacol., 2001; 423: 203-210
80. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G.: Activation of peripheral CB1 receptors in haemorrhagic shock. Nature, 1997; 390: 518-521
81. Wagner J.A., Varga K., Jarai Z., Kunos G.: Mesenteric vasodilation mediation by endothelial anandamide receptors. Hypertension, 1999; 33: 429-434
82. Wagner J.A., Varga K., Kunos G.: Cardiovascular actions of cannabinoids and their generation during shock. J. Mol. Med., 1998; 76: 824-836
83. White R., Hiley C.R.: The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br. J. Pharmacol., 1998; 125: 533-541
84. White R., Ho W.S., Bottrill F.E., Ford W.R., Hiley C.R.: Mechanisms of anandamide induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol., 2001; 134: 921-929
85. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Högestätt E.D.: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999; 400: 452-457